Women in Pharma: Insmed’s CFO on what is most fulfilling about working in life sciences

Sara Bonstein [Image courtesy of Insmed]

In January 2020, rare disease biopharma Insmed (Nasdaq: INSM) hired Sara Bonstein as its chief financial officer. At that point, Bonstein had more than 15 years of operational and financial experience in the life sciences industry.

In the following interview highlighting her role as a female pharma leader, Bonstein shares what initially attracted her to drug discovery and development and which projects at Insmed she finds most rewarding. She also provides perspective on leadership skills and what the industry can do to promote greater participation of young women in the pharma industry — especially in senior finance roles.

What first drew you to drug discovery and development? When did you first know you wanted to be in the industry?

Bonstein: During my freshman and sophomore years of college, Johnson & Johnson was recruiting on campus and I went to the informa…

Read more
  • 0

An inside look at Insmed

Many large drug developers employ individual groups or teams independently working on discrete steps in the drug development process.

Rare disease biopharma Insmed (NSDQ:INSM) differentiates itself through its focus on patients with rare diseases. To that end, the company works to ensure collaboration between various departments to consider questions related to the applicability of a given molecule and the potential impact it could have on patients.

The company has won FDA approval for Arikayce (amikacin liposome inhalation suspension), a novel treatment of Mycobacterium avium complex (MAC) lung disease in conjunction with an antibacterial drug regimen. 

Dr. Martina Flammer

“Many companies speak about patient focus and patient-centricity,” acknowledged Dr. Martina Flammer, the company’s chief medical officer. But often, that focus can be intermittent or can begin midway through development.

Read more
  • 0